Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, CA.
Department of Pharmacology, University of California, San Diego, La Jolla, CA.
Diabetes. 2019 Jul;68(7):1415-1426. doi: 10.2337/db18-1307. Epub 2019 Apr 22.
The composition of the gastrointestinal microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose homeostasis remain to be defined. Here we show that blood and intestinal levels of the microbiota-produced formyl peptide, formyl-methionyl-leucyl-phenylalanine, are elevated in high-fat diet-induced obese mice. Genetic or pharmacological inhibition of the formyl peptide receptor Fpr1 leads to increased insulin levels and improved glucose tolerance, dependent upon glucagon-like peptide 1. Obese Fpr1 knockout mice also display an altered microbiome, exemplifying the dynamic relationship between host metabolism and microbiota. Overall, we describe a new mechanism by which the gut microbiota can modulate glucose metabolism, providing a potential approach for the treatment of metabolic disease.
胃肠道微生物组的组成和相关代谢物随着饮食和肥胖的发展而发生显著变化。尽管已经描述了许多相关性,但这些变化与葡萄糖稳态之间的具体机制联系仍有待确定。在这里,我们表明,高脂肪饮食诱导的肥胖小鼠的血液和肠道中微生物产生的甲酰肽,即甲酰甲硫氨酰亮氨酰苯丙氨酸的水平升高。甲酰肽受体 Fpr1 的基因或药物抑制导致胰岛素水平升高和葡萄糖耐量改善,这依赖于胰高血糖素样肽 1。肥胖的 Fpr1 基因敲除小鼠也表现出微生物组的改变,体现了宿主代谢和微生物组之间的动态关系。总的来说,我们描述了一种肠道微生物组可以调节葡萄糖代谢的新机制,为代谢性疾病的治疗提供了一种潜在的方法。